The primary objective of this diagnostic trial was to evaluate the sensitivity of [18F]F-PSMA-1007 PET/CT defined as the ratio between the number of [18F]F-PSMA-1007 PET/CT positive patients and the number of prostate cancer patients with biochemical relapse and negative standard imaging. The gene discussed is FOLH1; the disease is prostate carcinoma.